Search
Prothena Corporation PLC
PRTAAdd to Watchlist
9.690USD
+0.110+1.15%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
514.32MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+1.15%
5 Days
-3.29%
1 Month
+4.76%
6 Months
+5.33%
Year to Date
+1.47%
1 Year
+50.58%
Key Figures
9.610Open
10.150High
462.88KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.87%Turnover Ratio
9.580Prev. Close
9.570Low
3.14MTurnover
LossP/E Static
1.65P/B
0.00%Div Yield TTM
-35.77%ROA
11.80052wk High
1.09Volume Ratio
-122.31MNet Profit
53.08MShares
-2.8070EPS TTM
-0.25Beta
-40.30%ROE
4.42252wk Low
6.05%Amplitude
100.00%Gross Margin
514.32MMarket Cap
1.22Reward/Risk
2.93%Risk Rate
TradingKey Stock Score of Prothena Corporation PLC
Currency: USD Updated: 2026-07-02Key Insights
Prothena Corporation PLC's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 72 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 21.40.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Prothena Corporation PLC's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Prothena Corporation PLC Highlights
StrengthsRisks
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
Growing
The company is in a growing phase, with the latest annual income totaling USD 9.68M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 9.68M.
Fairly Valued
The company’s latest PE is -3.45, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 50.39M shares, decreasing 22.37% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 387.84K shares of this stock.
Analyst Rating
Based on
6
analysts
Hold
Current Rating
21.400
Target Price
+123.38%
Upside Space
Prothena Corporation PLC News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Prothena Corporation PLC Info
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
Ticker SymbolPRTA
CompanyProthena Corporation PLC
CEOKinney (Gene G)
Websitehttps://www.prothena.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Prothena Corporation PLC (PRTA)?
The current price of Prothena Corporation PLC (PRTA) is 9.69.
What is the symbol of Prothena Corporation PLC?
The ticker symbol of Prothena Corporation PLC is PRTA.
What is the 52-week high of Prothena Corporation PLC?
The 52-week high of Prothena Corporation PLC is 11.80.
What is the 52-week low of Prothena Corporation PLC?
The 52-week low of Prothena Corporation PLC is 4.42.
What is the market capitalization of Prothena Corporation PLC?
The market capitalization of Prothena Corporation PLC is 514.32M.
Is Prothena Corporation PLC (PRTA) currently rated as Buy, Hold, or Sell?
According to analysts, Prothena Corporation PLC (PRTA) has an overall rating of signal_hold, with a price target of 21.40.
What is the Earnings Per Share (EPS TTM) of Prothena Corporation PLC (PRTA)?
The Earnings Per Share (EPS TTM) of Prothena Corporation PLC (PRTA) is -4.53.